Rosenblatt has acted for WH Ireland Limited on a placing by Verona Pharma plc to raise £3.25m. WH Ireland is nominated adviser and broker to Verona Pharma, a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases.
Approximately £2.18m was raised within Verona Pharma's existing authority to issue new shares and the remainder has been placed conditional on shareholder approval at a general meeting convened for 5 January 2012.
Nick Foss-Pedersen and Gerard Dempsey from Rosenblatt's corporate group advised WH Ireland on the placing.